IRIS

LA MONICA, Silvia

LA MONICA, Silvia  

Dipartimento di Medicina e Chirurgia  

Mostra records
Risultati 1 - 20 di 104 (tempo di esecuzione: 0.041 secondi).
Titolo Data di pubblicazione Autore(i) File
155P Antitumoral efficacy of dual blockade of EGFR signaling by osimertinib in combination with selumetinib or cetuximab in activated EGFR human NSCLC tumor models 1-gen-2018 Morgillo, F.; Corte, C. M. Della; Alfieri, R.; Petronini, P.; La Monica, S.; Papaccio, F.; Ciardiello, F.
A New ABCB1 Inhibitor Enhances the Anticancer Effect of Doxorubicin in Both In Vitro and In Vivo Models of NSCLC 1-gen-2023 Adorni, Maria Pia; Galetti, Maricla; La Monica, Silvia; Incerti, Matteo; Ruffoni, Alessandro; Elviri, Lisa; Zanotti, Ilaria; Papotti, Bianca; Cavallo, Delia; Alfieri, Roberta; Petronini, Pier Giorgio; Bernini, Franco
A sulfonyl fluoride derivative inhibits EGFR L858R/T790M/C797S by covalent modification of the catalytic lysine 1-gen-2021 Ferlenghi, F; Scalvini, L; Vacondio, F; Castelli, R; Bozza, N; Marseglia, G; Rivara, S; Lodola, A; La Monica, S; Minari, R; Petronini, Pg; Alfieri, R; Tiseo, M; Mor, M.
Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion 1-gen-2019 La Monica, S.; Minari, R.; Cretella, D.; Bonelli, M.; Fumarola, C.; Cavazzoni, A.; Galetti, M.; Digiacomo, G.; Riccardi, F.; Petronini, P. G.; Tiseo, M.; Alfieri, R.
Afatinib therapy in case of EGFR G724S emergence as resistance mechanism to osimertinib 1-gen-2021 Minari, R.; Leonetti, A.; Gnetti, L.; Zielli, T.; Ventura, L.; Bottarelli, L.; Lagrasta, C.; la Monica, S.; Petronini, P. G.; Alfieri, R.; Tiseo, M.
Amino acid signaling through the mammalian target of rapamycin (mTOR) pathway: Role of glutamine and of cell shrinkage 1-gen-2005 Fumarola, C; La Monica, S; Guidotti, Gg
Anti-proliferative and pro-apoptotic effects of Sorafenib in breast cancer cells in vitro. 1-gen-2010 Fumarola, Claudia; Bonelli, Mara; K., Airoud; Alfieri, Roberta; Cavazzoni, Andrea; Galetti, Maricla; LA MONICA, Silvia; D., Generali; Petronini, Pier Giorgio
Anti-proliferative effect of combining Letrozole with Sorafenib in MCF-7/Arom-1 breast cancer cells 1-gen-2008 Bonelli, Mara; Fumarola, Claudia; Alfieri, Roberta; Gatti, Rita; Belletti, Silvana; LA MONICA, Silvia; Galetti, M; Cavazzoni, Andrea; Frazzi, A; Bottini, A; Bergamini, L; Lynch, M; Harris, Al; Fox, Sb; Generali, Dg
Anti-proliferative effect of letrozole and sorafenib in MCF-7/AROM-1 breast cancer cells 1-gen-2008 Bonelli, Mara; Fumarola, Claudia; Alfieri, Roberta; LA MONICA, Silvia; Cavazzoni, Andrea; Galetti, M; Gatti, Rita; Belletti, Silvana; Bottini, A; Generali, D; Petronini, Pier Giorgio
Antitumor Efficacy of Dual Blockade of EGFR Signaling by Osimertinib in Combination With Selumetinib or Cetuximab in Activated EGFR Human NCLC Tumor Models 1-gen-2018 Della Corte, Carminia Maria; Ciaramella, Vincenza; Cardone, Claudia; La Monica, Silvia; Alfieri, Roberta; Petronini, Pier Giorgio; Malapelle, Umberto; Vigliar, Elena; Pepe, Francesco; Troncone, Giancarlo; Castellone, Maria Domenica; Troiani, Teresa; Martinelli, Erika; Ciardiello, Fortunato; Morgillo, Floriana
Bone marrow endothelial cells carry bcr/abl fusion gene from chronic myeloid leukemia patients 1-gen-2002 Rizzoli, Vittorio; Sammarelli, G.; Colla, S; Lazzaretti, M.; LA MONICA, S.; Roti, Giovanni; Hojden, M; Bonomini, S.; Sala, Roberto; Mangoni, L.; Genestretti, G.; Fattori, Pp; Giuliani, N.
Bone marrow endothelial cells carry bcr/abl fusion gene from chronic myeloid leukemia patients 1-gen-2002 Rizzoli, V.; Sammarelli, Gabriella; Colla, S; Lazzaretti, M.; LA MONICA, S.; Roti, Giovanni; Hojden, M; Bonomini, S.; Sala, Roberto; Mangoni, L.; Genestretti, G.
Bone marrow endothelial cells carry bcr/abl fusion gene from chronic myeloid leukemia patients 1-gen-2002 Rizzoli, V.; Sammarelli, G.; Colla, S; Lazzaretti, M.; LA MONICA, S.; Roti, Giovanni; Hojden, M; Bonomini, S.; Sala, Roberto; Mangoni, L.; Genestretti, G.; Fattori, Pp; Giuliani, Nicola
CDK4/6 Inhibition Enhances the Efficacy of Standard Chemotherapy Treatment in Malignant Pleural Mesothelioma Cells 1-gen-2022 Terenziani, Rita; Galetti, Maricla; La Monica, Silvia; Fumarola, Claudia; Zoppi, Silvia; Alfieri, Roberta; Digiacomo, Graziana; Cavazzoni, Andrea; Cavallo, Delia; Corradi, Massimo; Tiseo, Marcello; Petronini, Pier Giorgio; Bonelli, Mara
CDK4/6 INHIBITORS AS A NEW THERAPEUTIC APPROACH IN MESOTHELIOMA MODELS 1-gen-2023 La Monica, S.; Galetti, M.; Alfieri, R.; Cavazzoni, A.; Fumarola, C.; De Forni, D.; Lori, F.; Petronini, P. G.; Bonelli, M.
CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells 1-gen-2022 Digiacomo, Graziana; Fumarola, Claudia; La Monica, Silvia; Bonelli, Mara; Cavazzoni, Andrea; Galetti, Maricla; Terenziani, Rita; Eltayeb, Kamal; Volta, Francesco; Zoppi, Silvia; Bertolini, Patrizia; Missale, Gabriele; Alfieri, Roberta; Petronini, Pier Giorgio
CDK4/6 inhibitors overcome resistance to osimertinib in NSCLC cell lines independently from resistance mechanisms 1-gen-2019 Cretella, D; La Monica, S; Minari, R; Cavazzoni, A; Galetti, M; Petronini, P. G.; Tiseo, M; Alfieri, R.
Cell size reduction induced by inhibition of the mTOR/S6K signaling pathway protects Jurkat cells from apoptosis 1-gen-2005 Fumarola, Claudia; LA MONICA, Silvia; Alfieri, Roberta; Borra, Elena; Guidotti, G. G.
Characterization of gefitinib uptake in NSCLC cell lines 1-gen-2009 M. Galetti M., ; Alfieri, Roberta; Bonelli, Mara; Cavazzoni, Andrea; Fumarola, Claudia; LA MONICA, Silvia; Tiseo, M.; Ardizzoni, Andrea; Petronini, Pier Giorgio
Combination of EGFR-TKIs and chemotherapy in advanced EGFR mutated NSCLC: review of the literature and future perspectives 1-gen-2020 Rebuzzi, Sara Elena; Alfieri, Roberta; La Monica, Silvia; Minari, Roberta; Petronini, Pier Giorgio; Tiseo, Marcello